Orient Pharma Co. Ltd. (4166) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of Orient Pharma Co. Ltd. stock TWD 27.27, price TWD 22.55, upside +20.9%, quality 55 out of 100. Rating: undervalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range 14.30 TWD – 45.70 TWD · fair‑value band 17.88 TWD – 36.04 TWD · the 22.55 TWD price screens below the 27.27 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow Orient Pharma Co. in your weekly email
Every Wednesday you see whether Orient Pharma Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Orient Pharma Co., Ltd. engages in the development of new drugs in Taiwan and internationally.
Show moreShow less
It offers cardiovascular drugs, such as Pitator and Tonvasca for lipid suppression, as well as Zulitor, a lipid lowering drug; psychotropic drugs, including Trokendi XR extended, Methydur, and powder and solvent for prolonged-release suspension for injection.
The company was founded in 2008 and is based in Taipei, Taiwan.
Stock analysis
Orient Pharma Co. Ltd. (4166) currently trades at 22.55 TWD, while our model-based Fair Value estimate is 27.27 TWD, implying the stock looks roughly 17% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 30.93 TWD per share, and 13 of the 24 models we run sit above the 22.55 TWD price.
Bear case: the Asset-Based group reads lowest at 3.64 TWD, and 11 of the 24 models stay below the price. Data coverage for this calculation is low.
Scenario range: 17.88 TWD (bear) to 36.04 TWD (bull), the price of 22.55 TWD sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 55/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Orient Pharma Co. Ltd. reported revenue of 1.4B TWD in FY2025 versus 463M TWD in FY2021, a compound +31.9%/yr. Reported net income was 208M TWD in FY2025.
Key figures
Market cap 5.5B TWD (≈ $167M) Micro · P/E ratio 22.8 · P/S ratio 3.62 · EPS (TTM) 0.9900 TWD · Net margin 15.5% · Return on equity 10.4% · Return on assets (EBIT) 2.0% (5-year average) · Operating margin 18.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 53 out of 100 (low confidence).
What moves the price
The share trades about 20% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 21%, 4166 screens cheaper than that median.
Fair Value models
Bear17.88 TWDFair Value 27.27 TWDBull36.04 TWD
Price 22.55 TWD · Upside +20.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (0.8490 TWD per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.95/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+14.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+39.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+27.7%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+25.8%
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−38.9% (2020) → 19.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: rate outside our plausibility band
not computed
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+11.7%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Taiwan: IMF forecast 1.6% a year to 2030, 1.5% from 2016 to 2025) that is about +10.0% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 551 stocks
Beats the industry median on 8/12 measures
Overall it ranks above its industry peers.
Valuation
Quality Score55 · Below median
Fair Value upside+20.9% · Above median
Profitability
Return on equity (12 months)10.4% · Above median
Return on assets7.1% · Above median
Net margin (12 months)15.5% · Top 25%
Operating margin (12 months)18.3% · Above median
Growth and dividend
Revenue growth (quarter YoY)31.2% · Top 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/E (12 months)22.8× · Pricier than median
P/B2.14× · Pricier than median
P/S (12 months)3.62× · Pricier than median
Price / free cash flow (fiscal year)17.7× · Cheaper than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Orient Pharma Co. Ltd. (4166) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of 27.27 TWD versus a price of 22.55 TWD, about +21% upside (undervalued).
What is the fair value of 4166?
Our model-based fair value for Orient Pharma Co. Ltd. is 27.27 TWD (as of Nov 8, 2026), built from audited fundamentals. The current price: 22.55 TWD.
What is the quality score of 4166?
Orient Pharma Co. Ltd. has a Quality Score of 55/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Orient Pharma Co. Ltd. (4166)?
Our model-based price target is the fair value of 27.27 TWD (as of Nov 8, 2026) from 24 valuation models. Cautious scenario 17.88 TWD, optimistic scenario 36.04 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Orient Pharma Co. Ltd. stock forecast for 2026?
Our models put fair value at 27.27 TWD, about +21% upside versus a price of 22.55 TWD (undervalued). Cautious scenario 17.88 TWD, optimistic scenario 36.04 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Orient Pharma Co. Ltd. (4166)?
Orient Pharma Co. Ltd. reported trailing-twelve-month revenue of about 1.5B TWD (latest available figure, as of Nov 8, 2026).
What growth is priced into Orient Pharma Co. Ltd. (4166)?
For today's price to be fair in a discounted-cash-flow model, Orient Pharma Co. Ltd. would have to grow free cash flow by +11.7 % per year for five years (discount rate 11.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +27.7 % per year. As of Nov 8, 2026.
What discount rate (WACC) does the fair value of 4166 use?
Our models discount Orient Pharma Co. Ltd. at 11.8 %: a base by market capitalisation (micro), damped by beta 0.04, country premium for Taiwan. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Orient Pharma Co. Ltd. that is +11.7 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.8 %) and the same formula as our fair value.
How much growth has Orient Pharma Co. Ltd. (4166) delivered so far?
Over the past 5 years revenue at Orient Pharma Co. Ltd. grew +27.7 % a year. The price currently implies free-cash-flow growth of +11.7 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Orient Pharma Co. Ltd. (4166) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Orient Pharma Co. Ltd. (+11.7 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Orient Pharma Co. Ltd. (4166)?
The free-cash-flow yield on the price is 5.66 %: that much free cash flow Orient Pharma Co. Ltd. produces per unit of market value. When it exceeds the discount rate of our models (11.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Orient Pharma Co. Ltd. (4166)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Orient Pharma Co. Ltd. it is 27.27 TWD per share (as of Nov 8, 2026), against a price of 22.55 TWD. It is the blended result of 24 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Orient Pharma Co. Ltd. stock overvalued or undervalued in 2026?
As of Nov 8, 2026, 4166 trades below its calculated fair value: price 22.55 TWD, fair value 27.27 TWD, a gap of about +21% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 4166?
No. The price is what the market pays today (22.55 TWD); the fair value is what the company's own numbers justify (27.27 TWD). For Orient Pharma Co. Ltd. the two are 4.72 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Orient Pharma Co. Ltd. worth?
The market values Orient Pharma Co. Ltd. at about 5.5B TWD (market capitalisation, as of Nov 8, 2026). Per share that is 22.55 TWD; our models calculate a fair value of 27.27 TWD per share.
What do the bullish and bearish scenarios say about 4166?
Our models span a range for Orient Pharma Co. Ltd.: cautious scenario 17.88 TWD, base 27.27 TWD, optimistic 36.04 TWD per share (as of Nov 8, 2026, price 22.55 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 4166?
Orient Pharma Co. Ltd. trades at a price-to-earnings ratio of 22.8 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 27.27 TWD is built from several models across several years. Other multiples: P/B 2.1, P/S 3.6, EV/EBITDA 12.4.
How solid is the balance sheet of Orient Pharma Co. Ltd. (4166)?
Balance-sheet figures for Orient Pharma Co. Ltd. (as of Nov 8, 2026): return on equity 10.4%. They feed the Quality Score of 55/100, which measures business quality independently of the share price.
How far is 4166 from its 52-week high?
Orient Pharma Co. Ltd. trades at 22.55 TWD, about 20% below its 52-week high of 28.10 TWD and 3% above the low of 22.00 TWD (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 27.27 TWD is for.
Which stocks are comparable to Orient Pharma Co. Ltd.?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Orient Pharma Co. Ltd. stock attractive at the current price?
The data as of Nov 8, 2026: price 22.55 TWD, calculated fair value 27.27 TWD (+21%), Quality Score 55/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 4166 calculated?
We run Orient Pharma Co. Ltd. through 24 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 27.27 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Orient Pharma Co. Ltd. currently trades 17% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Orient Pharma Co. Ltd. (4166)?
The closing price on Nov 9, 2026 was 22.55 TWD. Our model-based fair value is 27.27 TWD, about +21% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Orient Pharma Co. Ltd. right now?
Solid quality (55/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (17.88 TWD to 36.04 TWD) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Orient Pharma Co. Ltd.
How large is the market capitalisation of Orient Pharma Co. Ltd. (4166)?
The market capitalisation of Orient Pharma Co. Ltd. is 5.5B TWD (≈ $167M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Orient Pharma Co. Ltd. (4166)?
The price-to-sales ratio of Orient Pharma Co. Ltd. is 3.62 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Orient Pharma Co. Ltd. (4166)?
Earnings per share at Orient Pharma Co. Ltd. are 0.9900 TWD (price ÷ EPS = P/E 22.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Orient Pharma Co. Ltd. (4166)?
The net margin of Orient Pharma Co. Ltd. is 15.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Orient Pharma Co. Ltd. (4166)?
The return on equity (ROE) of Orient Pharma Co. Ltd. is 10.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Orient Pharma Co. Ltd. (4166)?
On an EBIT basis the return on assets of Orient Pharma Co. Ltd. is 2.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Orient Pharma Co. Ltd. (4166)?
The operating margin of Orient Pharma Co. Ltd. is 18.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Orient Pharma Co. Ltd. (4166)?
Revenue at Orient Pharma Co. Ltd. is growing +31.2% versus a year earlier (3y avg +39.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Orient Pharma Co. Ltd. (4166)?
Earnings per share at Orient Pharma Co. Ltd. are growing +195% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Orient Pharma Co. Ltd. (4166) carry?
The net debt of Orient Pharma Co. Ltd. is 248M TWD (fiscal year 2024, ≈ 0.8 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Orient Pharma Co. Ltd. in the live analysis
One click puts Orient Pharma Co. Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 8, 2026